Trial · NCT03129126
The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
NCT03129126, Phase 2, Completed, Lipella Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis. Trials, record NCT03129126. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03129126
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
- NCT number
- NCT03129126
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 13 participants, actual
- Lead sponsor
- Lipella Pharmaceuticals, Inc.
- Conditions
- Hemorrhagic Cystitis
- Interventions
- LP-10
- First posted
- 2017-04-26
- Last updated
- 2023-12-11
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient Reported Mean episodes of visible blood | At every patient visit, up to 2 weeks following initial treatment | Pre-post changes in mean episodes of visible blood in urine (or blood clots) on 3-day bladder diaries at baseline and primary endpoint |
| Secondary | Urine Dipstick Mean episodes of Visible Blood | At every patient visit, up to 2 weeks following initial treatment | Mean episodes of visible blood in urine (or blood clots) and urine dipstick for quantitative grading of microscopic hematuria on bladder diaries |
| Secondary | Mean urine hemoglobin concentration | At every patient visit, up to 2 weeks following initial treatment | Mean urine hemoglobin concentration |
| Secondary | Urine analysis with microscopy | At every patient visit, up to 2 weeks following initial treatment | Urine analysis with microscopy including red blood cells per high power field test |
| Secondary | Whole blood Add to dictionary levels | At every patient visit, up to 2 weeks following initial treatment | Whole blood tacrolimus levels |
| Secondary | Blood chemistry and liver function test | At every patient visit, up to 2 weeks following initial treatment | Blood chemistry and liver function test |
| Secondary | Patient Reported Global Response Assessment Survey Score | At every patient visit, up to 2 weeks following initial treatment | Changes in Global Response Assessment (GRA) |
| Secondary | Patient Reported Urinary frequency | At every patient visit, up to 2 weeks following initial treatment | Changes in urinary frequency and incontinence measured on diaries |
| Secondary | Bladder Cystoscopy | At initial treatment and on final patient visit, up to 2 weeks following initial treatment | Cystoscopic changes in bladder |
| Secondary | Patient Reported Health Related Quality of Life Survey Score | At every patient visit, up to 2 weeks following initial treatment | Changes in Health Related Quality of Life (HRQOL) scores |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03129126
GET https://conductscience.org/api/trials/v1/NCT03129126/registered